fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Teleflex announces positive data showing that the UroLift System treating lower urinary tract symptoms due to benign prostatic hyperplasia relieves enlarged prostate symptoms while preserving patients’ sexual function.

Written by | 19 May 2020

Teleflex Incorporated announced that data from two analyses of the UroLift System were presented at the American Urological Association (AUA) 2020 Virtual Science event. This new multimedia reinvention… read more.

Phase III clinical study of JTA 004 commences to reduce osteoarthritis pain in the knee.- Bone Therapeutics

Written by | 18 May 2020

Bone Therapeutics announces it has commenced treating the first patients for the pivotal JTA 004 phase III clinical study in Hong Kong SAR. Several clinical trial sites in… read more.

Phase III clinical study of JTA 004 commences to reduce osteoarthritis pain in the knee.- Bone Therapeutics

Written by | 18 May 2020

Bone Therapeutics announces it has commenced treating the first patients for the pivotal JTA 004 phase III clinical study in Hong Kong SAR. Several clinical trial sites in… read more.

Health Canada approves first COVID-19 serological test for use in the country to detect COVID-19 antibodies. DiaSorin

Written by | 14 May 2020

Health Canada says it has authorized the first COVID-19 serological test for use in the country to detect antibodies specific to the virus. DiaSorin, an Italian multinational biotechnology… read more.

NIH clinical trial testing antiviral remdesivir plus anti-inflammatory baricitinib for COVID-19 begins.

Written by | 13 May 2020

A randomized, controlled clinical trial evaluating the safety and efficacy of a treatment regimen of the investigational antiviral remdesivir plus the anti-inflammatory drug baricitinib for coronavirus disease 2019… read more.

FDA gives emergency use authorisation for SARS-CoV-2 IgG test for COVID-19 diagnostics.- Abbott

Written by | 12 May 2020

Abbott announced that the FDA issued Emergency Use Authorization (EUA) for the company’s SARS-CoV-2 IgG lab-based serology blood test on the Alinity i system. Abbott plans to ship… read more.

Vital Patch secures FDA Emergency Use Authorization for cardiac monitoring in COVID- 19 patients.- VitalConnect

Written by | 12 May 2020

VitalConnect announced that it has received FDA Emergency Use Authorization status for use of its VitalPatch to detect changes in the QT interval of hospitalized patients undergoing drug… read more.

FDA grants emergency use authorisation for Sofia 2 SARS Antigen Test for COVID-19 detection.- Quidel Corp

Written by | 11 May 2020

Quidel Corporation announced that it has received Emergency Use Authorization (EUA) from the FDA to market its Sofia 2 SARS Antigen rapid point-of-care test to be used with… read more.

FDA grants emergency use authorization to the Zero Contact COVID-19 test kit as a saliva-based diagnostic for at home use to detect COVID-19.- Vitagene

Written by | 11 May 2020

Vitagene has announced the availability of 50,000 FDA authorized at home Zero-Contact or Saliva-based COVID-19 test kits for use during the current public emergency to detect COVID-19. Vitagene… read more.

La Jolla Pharmaceutical Company to provide Giapreza (Angiotensin II) for emergency medical program in patients with septic shock due to COVID-19 at CHIREC Delta Hospital, Brussels, Belgium.

Written by | 11 May 2020

La Jolla Pharmaceutical Company announced that it is providing Giapreza (angiotensin II) for an emergency medical program in patients with septic shock due to COVID-19 at the Centre… read more.

Health Canada approves Real-Time Fluorescent RT-PCR Kit for detecting SARS-CoV-2.- BGI Genomics

Written by | 8 May 2020

BGI Genomics announced that its subsidiary BGI Americas Corporation has received authorization under Interim Order from Health Canada to supply its Real-Time Fluorescent RT-PCR Kit for Detecting SARS-CoV-2… read more.

TAVO + Keytruda demonstrated 41% overall response rate and 36% complete response in a late-stage metastatic melanoma study featured in ‘Clinical Cancer Research’.- Oncosec Medical.

Written by | 8 May 2020

Oncosec Medical announced published data in Clinical Cancer Research that demonstrated its lead product candidate, TAVO (interleukin-12 or “IL-12” plasmid), in combination with the anti-PD-1 checkpoint inhibitor Keytruda… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.